2026 Q1 Portfolio Activity
In 2026 Q1, Knott David M Jr maintained a portfolio of 96 distinct positions. The most significant new addition was Iovance Biotherapeutics, Inc., now representing 3.34% of the total fund value. They heavily accumulated shares in Agios Pharmaceutical, Inc., increasing the position by 417.0%. Conversely, Knott David M Jr completely exited their position in Calumet, Inc..
Position History
hover any row below to update
Loading…
Total Positions
96
Quarter
2026 Q1
Top Holding
GOOG (15.6%)
Top 10 Concentration
60.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 96
Knott David M Jr Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GOOG
Alphabet Inc-Cl...
|
Communication Services | 15.61% | 13.28% |
#1
2
Prev: #3
|
7.0 |
—
|
no change | no change |
P
S
|
91,420 | $26,228,398 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
APO
Apollo Global M...
|
Financial Services | 14.92% | 15.08% |
#2
Prev: #2
|
6.5 |
—
|
no change | no change |
P
S
|
225,000 | $25,069,500 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
SNDX
Syndax Pharmace...
|
Healthcare | 5.87% | 4.04% |
#3
1
Prev: #4
|
3.8 |
—
|
7,000 | 1.7% |
P
S
|
422,000 | $9,857,920 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BBIO
Bridgebio Pharm...
|
Healthcare | 3.98% | 3.01% |
#4
3
Prev: #7
|
4.1 |
—
|
5,000 | 5.9% |
P
S
|
90,000 | $6,683,400 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
PTGX
Protagonist The...
|
Healthcare | 3.95% | 2.95% |
#5
3
Prev: #8
|
2.6 |
—
|
-10,000 | -13.7% |
P
S
|
63,000 | $6,640,200 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
XERS
Xeris Biopharma...
|
Healthcare | 3.66% | 3.53% |
#6
1
Prev: #5
|
3.5 |
—
|
90,000 | 9.3% |
P
S
|
1,060,000 | $6,148,000 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
JPM
JPMorgan Chase ...
|
Financial Services | 3.41% | 2.91% |
#7
2
Prev: #9
|
2.4 |
—
|
no change | no change |
P
S
|
19,477 | $5,729,354 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
IOVA
Iovance Biother...
|
Healthcare | 3.34% | — |
#8
Prev: #—
|
4.8 |
—
|
1,600,000 | — |
NEW
|
1,600,000 | $5,616,000 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
LPL Financial H...
|
|
Unknown | 2.95% | — |
#9
Prev: #—
|
4.7 |
—
|
16,500 | — |
NEW
|
16,500 | $4,963,695 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
JAAA
Janus Henderson...
|
ETF | 2.80% | 2.19% |
#10
Prev: #10
|
2.1 |
—
|
no change | no change |
P
S
|
93,528 | $4,711,005 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ALKS
Alkermes PLC
|
Healthcare | 2.53% | 1.23% |
#11
4
Prev: #15
|
3.5 |
—
|
25,000 | 26.3% |
P
S
|
120,000 | $4,243,200 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TVTX
Travere Therape...
|
Healthcare | 2.49% | 3.29% |
#12
6
Prev: #6
|
1.0 |
—
|
-45,367 | -24.4% |
P
S
|
140,633 | $4,178,206 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
COGT
Cogent Bioscien...
|
Healthcare | 2.38% | 1.68% |
#13
Prev: #13
|
1.5 |
—
|
2,000 | 2.0% |
P
S
|
104,000 | $4,002,960 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VRDN
Viridian Therap...
|
Healthcare | 2.11% | 2.09% |
#14
3
Prev: #11
|
3.3 |
—
|
36,000 | 24.8% |
P
S
|
181,000 | $3,540,360 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
AGIO
Agios Pharmaceu...
|
Healthcare | 1.87% | 0.23% |
#15
35
Prev: #50
|
3.7 |
—
|
75,058 | 417.0% |
P
S
|
93,058 | $3,148,152 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
RLMD
Relmada Therape...
|
Healthcare | 1.82% | — |
#16
Prev: #—
|
4.2 |
—
|
439,300 | — |
NEW
|
439,300 | $3,057,528 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TGTX
TG Therapeutics...
|
Healthcare | 1.78% | 0.62% |
#17
9
Prev: #26
|
3.7 |
—
|
45,001 | 100.0% |
P
S
|
90,001 | $2,989,833 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CPRX
Catalyst Pharma...
|
Healthcare | 1.77% | 2.04% |
#18
6
Prev: #12
|
0.7 |
—
|
-69,000 | -36.5% |
P
S
|
120,000 | $2,971,200 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ACLX
Arcellx Inc
|
Healthcare | 1.33% | 0.78% |
#19
2
Prev: #21
|
0.5 |
—
|
-6,267 | -24.4% |
P
S
|
19,433 | $2,231,297 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
XBI
SPDR S&P Biotec...
|
ETF | 1.14% | 0.73% |
#20
2
Prev: #22
|
2.5 |
—
|
2,000 | 15.4% |
P
S
|
15,000 | $1,916,100 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
AB
AllianceBernste...
|
Financial Services | 1.07% | 0.86% |
#21
1
Prev: #20
|
1.4 |
—
|
no change | no change |
P
S
|
48,000 | $1,797,120 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 1.04% | 1.34% |
#22
8
Prev: #14
|
0.4 |
—
|
-40,000 | -33.0% |
P
S
|
81,241 | $1,754,806 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
DCGO
DocGo, Inc.
|
Healthcare | 1.00% | 1.09% |
#23
7
Prev: #16
|
1.4 |
—
|
no change | no change |
P
S
|
2,670,850 | $1,680,232 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CYBN
Cybin Inc
|
Unknown | 1.00% | 1.08% |
#24
7
Prev: #17
|
2.9 |
—
|
64,818 | 22.7% |
P
S
|
350,000 | $1,680,000 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CYTK
Cytokinetics, I...
|
Healthcare | 0.93% | 1.00% |
#25
7
Prev: #18
|
0.4 |
—
|
-10,356 | -30.5% |
P
S
|
23,644 | $1,558,376 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CNTA
Centessa Pharma...
|
Healthcare | 0.92% | 0.05% |
#26
39
Prev: #65
|
3.4 |
—
|
35,000 | 875.0% |
P
S
|
39,000 | $1,549,080 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ATRC
AtriCure, Inc.
|
Healthcare | 0.87% | 0.94% |
#27
8
Prev: #19
|
1.3 |
—
|
no change | no change |
P
S
|
51,400 | $1,466,442 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ARDX
Ardelyx, Inc.
|
Healthcare | 0.74% | — |
#28
Prev: #—
|
3.8 |
—
|
207,000 | — |
NEW
|
207,000 | $1,239,930 | 2022 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CLOZ
The Panagram BB...
|
ETF | 0.73% | 0.59% |
#29
1
Prev: #28
|
1.3 |
—
|
no change | no change |
P
S
|
47,807 | $1,226,250 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
JNJ
Johnson & Johns...
|
Healthcare | 0.72% | 0.66% |
#30
5
Prev: #25
|
0.3 |
—
|
-2,000 | -28.9% |
P
S
|
4,922 | $1,203,134 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
RZLT
Rezolute, Inc.
|
Healthcare | 0.67% | 0.37% |
#31
8
Prev: #39
|
2.3 |
—
|
30,000 | 8.8% |
P
S
|
370,000 | $1,128,500 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
OBIO
Orchestra Biome...
|
Healthcare | 0.64% | 0.48% |
#32
2
Prev: #34
|
0.8 |
—
|
3,651 | 1.5% |
P
S
|
253,651 | $1,078,017 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MDGL
Madrigal Pharma...
|
Healthcare | 0.62% | 0.54% |
#33
2
Prev: #31
|
1.2 |
—
|
no change | no change |
P
S
|
2,000 | $1,046,940 | 2022 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VERA
Vera Therapeuti...
|
Healthcare | 0.62% | 0.61% |
#34
7
Prev: #27
|
1.2 |
—
|
no change | no change |
P
S
|
26,000 | $1,045,980 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
Connect Biophar...
|
|
Unknown | 0.60% | 0.26% |
#35
13
Prev: #48
|
3.2 |
—
|
187,835 | 93.9% |
P
S
|
387,835 | $1,016,128 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
IBB
iShares Biotech...
|
ETF | 0.55% | 0.43% |
#36
1
Prev: #35
|
1.2 |
—
|
no change | no change |
P
S
|
5,500 | $928,675 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
PFE
Pfizer Inc.
|
Healthcare | 0.54% | 0.37% |
#37
1
Prev: #38
|
1.2 |
—
|
no change | no change |
P
S
|
32,337 | $908,023 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BMY
Bristol-Myers S...
|
Healthcare | 0.49% | 0.55% |
#38
8
Prev: #30
|
0.2 |
—
|
-8,378 | -38.1% |
P
S
|
13,622 | $826,174 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CNQ
Canadian Natura...
|
Energy | 0.49% | 0.26% |
#39
8
Prev: #47
|
1.2 |
—
|
no change | no change |
P
S
|
16,800 | $818,664 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BIIB
Biogen Inc.
|
Healthcare | 0.44% | 0.49% |
#40
7
Prev: #33
|
0.2 |
—
|
-2,000 | -33.3% |
P
S
|
4,000 | $733,320 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
RARE
Ultragenyx Phar...
|
Healthcare | 0.41% | 0.21% |
#41
10
Prev: #51
|
3.2 |
—
|
13,063 | 65.3% |
P
S
|
33,069 | $692,796 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
AAPL
Apple Inc.
|
Technology | 0.38% | 0.31% |
#42
1
Prev: #41
|
1.2 |
—
|
no change | no change |
P
S
|
2,494 | $632,952 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MSFT
Microsoft Corpo...
|
Technology | 0.35% | 0.36% |
#43
3
Prev: #40
|
1.1 |
—
|
no change | no change |
P
S
|
1,600 | $592,272 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VSTM
Verastem Inc.
|
Healthcare | 0.33% | — |
#44
Prev: #—
|
3.6 |
—
|
104,000 | — |
NEW
|
104,000 | $551,200 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ADMA
ADMA Biologics,...
|
Healthcare | 0.32% | 0.51% |
#45
13
Prev: #32
|
1.1 |
—
|
no change | no change |
P
S
|
60,200 | $542,402 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
IBM
International B...
|
Technology | 0.31% | 0.29% |
#46
2
Prev: #44
|
1.1 |
—
|
no change | no change |
P
S
|
2,142 | $519,285 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
Biohaven Pharma...
|
|
Unknown | 0.31% | — |
#47
Prev: #—
|
3.6 |
—
|
60,720 | — |
NEW
|
60,720 | $513,691 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
PTHS
Pelthos Therape...
|
Healthcare | 0.26% | 0.28% |
#48
2
Prev: #46
|
2.1 |
—
|
1,792 | 9.3% |
P
S
|
21,073 | $442,744 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
KURA
Kura Oncology, ...
|
Healthcare | 0.26% | 0.19% |
#49
4
Prev: #53
|
2.6 |
—
|
13,558 | 34.6% |
P
S
|
52,767 | $428,996 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
EOLS
Evolus, Inc.
|
Healthcare | 0.24% | 0.31% |
#50
8
Prev: #42
|
1.1 |
—
|
no change | no change |
P
S
|
99,338 | $408,279 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 |
Showing 1-50 of 96 holdings